If you have been reading about 五肽 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
In January 2023, Foreign Minister Mauro Vieira announced Brazil's return to the Community of Latin American and Caribbean States (CELAC). During the 7th CELAC summit, Lula expressed support for a modernization of the South American customs union Mercosur and the creation of a common unit of account between Argentina and Brazil which other South American nations could also join to boost regional integration and skip US dollar dominance. On 25 January, during a trip to Uruguay, Lula called for the European Union-Mercosur trade deal to be sealed and a China-Mercosur trade agreement to be explored. Lula and Uruguayan president Luis Lacalle Pou held talks over infrastructure projects to be developed in Uruguay, including a joint Uruguayan-Brazilian administration of the Rivera International Airport. In March 2023, Uruguayan and Brazilian top officials jointly detailed the said infrastructure projects in Brasília. Brazil also invited Paraguay and Uruguay to join the works of the G20 ahead of the 2024 G20 Brazil summit, as Brazilian rotating presidency in the group was to begin on 1 December 2023. In December 2024, during a summit in Montevideo attended by Lula and Ursula von der Leyen, Mercosur struck a definitive free trade agreement with the European Union representing nearly a quarter of the global gross domestic product (GDP).
=== Phase 1 === AZD-4041 – orexin OX1 receptor antagonist – opioid-related disorders BI-1356225 – ghrelin O-acyltransferase (GOAT) inhibitor – opioid-related disorders Cebranopadol (GRT-6005; PRK-101; TRN-228) – μ-opioid receptor agonist, nociceptin receptor agonist – substance-related disorders CSX-1004 – monoclonal antibody against fentanyl – opioid-related disorders Dimethyltryptamine/harmine (DMT/harmine; RE-01) – combination of dimethyltryptamine (DMT) (serotonin 5-HT2A receptor agonist and serotonergic psychedelic) and harmine (monoamine oxidase inhibitor (MAOI) and other actions) – cocaine-related disorders DPI-125 (MCP-201) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – opioid-related disorders Ibuprofen/ketotifen (SJP-005) – combination of ibuprofen (cyclooxygenase (COX) inhibitor/NSAID) and ketotifen (histamine H1 receptor antagonist, other actions) – opioid-related disorders Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – opioid-related disorders KNX-100 (SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator – opioid-related disorders, substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – cocaine-related disorders MEB-1170 – μ-opioid receptor biased agonist – opioid-related disorders Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, and serotonergic psychedelic – substance use disorders MST-01 – undefined mechanism of action – smoking withdrawal Nalmefene (AV-104; TH-104) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Naltrexone implantable pellets (BICX-102, BICX-104) – opioid receptor antagonist – alcoholism, opioid-related disorders, substance-related disorders Nezavist (DCUK-OEt) – peripherally selective GABAA receptor positive allosteric modulator (etomidate site) – alcoholism Noribogaine (DMX-1001) – various actions – alcoholism NRS-033 (nalmefene prodrug) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders OMS-527 (OMS-182399; OMS527) – phosphodiesterase PDE7 inhibitor – cocaine-related disorders Psilocybin (MLS-101/MLS101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – opioid-related disorders Smoking cessation therapeutics - Astraea Therapeutics – nicotinic acetylcholine receptor antagonists – smoking withdrawal SXC-2023 – cystine/glutamate transporter (SLC7A11) – cocaine-related disorders Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – opioid-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – cocaine-related disorders, substance-related disorders
In crystallography, polymorphism is the phenomenon where a compound can crystallize into more than one crystal structure; in the case of elements the term allotropy is sometimes used. An example of polymorphism is titanium dioxide (TiO2), which occurs in four known natural polymorphic forms (minerals with the same composition but different structure): brookite (orthorhombic), akaogiite (monoclinic), anatase (tetragonal) and rutile (tetragonal). Eilhard Mitscherlich discovered polymorphism ("dimorphism") in his studies of sodium phosphate (1821) and sulphur (1823). In the 1830s the development of the microscope enhanced observations of polymorphism and aided Moritz Ludwig Frankenheim's studies. Frankenheim was able to demonstrate methods to induce crystal phase changes, for example the use of solvents or physical scratching, and formally summarized his findings on the nature of polymorphism. Soon after, the more sophisticated polarized light microscope came into use, and it provided better visualization of crystalline phases allowing crystallographers to distinguish between different polymorphs. The hot stage was invented and fitted to a polarized light microscope by Otto Lehmann in about 1877. This invention helped crystallographers determine melting points and observe polymorphic transitions. The first polymorphic organic substance, benzamide, was discovered by Friedrich Wöhler and Justus von Liebig in 1832. In 1870 Paul Groth defined wikt:morphotropy as the state of two crystals whose similar physical structure is due to similar chemical composition.
Sources: en.wikipedia.org
Damaged DNA – Over-exposure to UV radiation during preparation of DNA for ligation can damage the DNA and significantly reduce transformation efficiency. A higher-wavelength UV radiation (365 nm) which cause less damage to DNA should be used if it is necessary work for work on the DNA on a UV transilluminator for an extended period of time. Addition of cytidine or guanosine to the electrophoresis buffer at 1 mM concentration however may protect the DNA from damage. Incorrect usage of CIAP or its inefficient inactivation or removal. Excessive amount of DNA used. Incomplete DNA digest – The vector DNA that is incompletely digested will give rise to a high background, and this may be checked by doing a ligation without insert as a control. Insert that is not completely digested will also not ligate properly and circularize. When digesting a PCR product, make sure that sufficient extra bases have been added to the 5'-ends of the oligonucleotides used for PCR as many restriction enzymes require a minimum number of extra basepairs for efficient digest. The information on the minimum basepair required is available from restriction enzyme suppliers such as in the catalog of New England Biolabs. Incomplete ligation – Blunt-ends DNA (e.g. SmaI) and some sticky-ends DNA (e.g. NdeI) that have low-melting temperature require more ligase and longer incubation time. Protein expressed from ligated gene insert is toxic to cells. Homologous sequence in insert to sequence in plasmid DNA resulting in deletion. High concentration of EDTA or salts that acts as an inhibitors.
==== Magnetic resonance and radio-frequency pulses ==== A perturbation of nuclear spin orientations from equilibrium will occur only when an oscillating magnetic field is applied whose frequency νrf sufficiently closely matches the Larmor precession frequency νL of the nuclear magnetization. The populations of the spin-up and -down energy levels then undergo Rabi oscillations, which are analyzed most easily in terms of precession of the spin magnetization around the effective magnetic field in a reference frame rotating with the frequency νrf. The stronger the oscillating field, the faster the Rabi oscillations or the precession around the effective field in the rotating frame. After a certain time on the order of 2–1000 microseconds, a resonant RF pulse flips the spin magnetization to the transverse plane, i.e. it makes an angle of 90° with the constant magnetic field B0 ("90° pulse"), while after a twice longer time, the initial magnetization has been inverted ("180° pulse"). It is the transverse magnetization generated by a resonant oscillating field which is usually detected in NMR, during application of the relatively weak RF field in old-fashioned continuous-wave NMR, or after the relatively strong RF pulse in modern pulsed NMR.
== History == A high yield and efficient synthesis of 2,6-DCBQ was first provided in 1886 by the chemist Kollrep A. during a systematic investigation into derivatives of phenols. Kollrepp utilized p-nitrophenol as a starting material, converting it into mono- and dichlornated benzoquinones making vibrant yellow cristalline structure. Researchers in 1932 found an optical method for studying reversible organic oxidation-reduction systems, by using hydroquinones to determine equilibrium constants. In 1956 Wessels and van der Veen explored how chlorinated quinones could shuttle electrons. By researching the action of benzoquinones on the Hill reaction. It became a standard tool for isolating the activity of Photosystem II, because of its specific redox potential. Qin et al. detected and quantified 2,6-DCBQ from Canadian municipal drinking water samples. By using highly sensitive liquid chromatography mass spectrometry, 2,6-DCBQ was identified as a major DBP formed during chlorination of raw water containing phenolic contaminants. Since this discovery, research about 2,6-DCBQ has shifted towards its role in human health.
Sources: en.wikipedia.org
Copper peptide GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. The tripeptide has strong affinity for copper(II) and was first isolated from human plasma. It can be found also in saliva and urine.
Mianserin appears to exert its effects via antagonism of histamine and serotonin receptors, and inhibition of norepinephrine reuptake. More specifically, it is an antagonist/inverse agonist at most, if not all sites of the histamine H1 receptor, serotonin 5-HT1D, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptors, and adrenergic α1- and α2-adrenergic receptors, and additionally a norepinephrine reuptake inhibitor. As an H1 receptor inverse agonist with high affinity, mianserin has strong antihistamine effects (e.g., sedation). Conversely, it has low affinity for the muscarinic acetylcholine receptors, and hence lacks anticholinergic properties. Mianserin has been found to be a low affinity but potentially significant partial agonist of the κ-opioid receptor (Ki = 1.7 μM; EC50 = 0.53 μM), similarly to some tricyclic antidepressants (TCAs). Blockade of the H1 and possibly α1-adrenergic receptors has sedative effects, and also antagonism of the 5-HT2A and α1-adrenergic receptors inhibits activation of intracellular phospholipase C (PLC), which seems to be a common target for several different classes of antidepressants. By antagonizing the somatodendritic and presynaptic α2-adrenergic receptors, which function predominantly as inhibitory autoreceptors and heteroreceptors, mianserin disinhibits the release of norepinephrine, dopamine, serotonin, and acetylcholine in various areas of the brain and body.
=== Official === President Joe Biden official website (archived) Presidential campaign website at the Wayback Machine (archived July 18, 2024) Obama White House biography (archived) Senator Joseph R. Biden (1973–2009)
== Pathophysiology == Coronary occlusion is caused by plaque inside of the blood vessels that direct oxygen rich blood to the heart. Plaque is caused by fatty deposits and scar tissue that cling to the walls of coronary arteries. The development of plaque takes years and leads to stenosis of the coronary arteries and progressively reduces blood flow. Due to the slower development of this condition, the body will adapt and create small blood vessels that circumvent the blockage. The small blood vessels form a natural bypass of the blockage, but often do not supply enough blood to meet an increased demand when stressors are applied like exercise. When a plaque has a greater than 50% diameter stenosis, the reduced blood flow through the coronary artery during exertion may lead to angina. Acute coronary events occur when a thrombus forms due to disruption of a plaque. In acute heart attack, occlusion is greater than in unstable angina, where arterial occlusion is not full blockage. Downstream embolism of thrombus may also produce microinfarcts.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.